Soaring Eagle Acquisition Corp.
Status: Closed Deal
U=S+W/5
W=S@11.5
| IPO Proceeds, $M | $1,725.00M |
|---|---|
| IPO Date | Feb 24, 2021 |
| CEO | Harry E. Sloan |
| Left Lead | Goldman Sachs |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24+6 |
| IPO Sector | General ▶ |
| IPO Geography | Global |
| Target Company | Ginkgo Bioworks |
| Deal Announced | May 11, 2021 |
| Deal Size, $M | $15,164.00M |
| Deal Sector | Healthcare |
| Deal Geography | Global |
| SEC Filings |
www.sec.gov 
|
| Approval Vote | Sep 14, 2021 |
| Amendment Vote | TBD |
| Closing Date | Sep 17, 2021 |
Formerly SRNG
DNA
DNA/W
| Price | $9.27 $0.23 |
|---|---|
| Last closing price | $9.11 |
| H/L, today | $9.05 / $9.38 |
| H/L, 52-week | $1.12 / $2.94 |
| Volume, today | 446,102 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in to view structure, cap table, and calendar of events.